Comparative Pharmacology
Head-to-head clinical analysis: BENZEDRINE versus FOCALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZEDRINE versus FOCALIN.
BENZEDRINE vs FOCALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzedrine (racemic amphetamine) releases dopamine and norepinephrine from presynaptic neurons, blocks their reuptake, and inhibits monoamine oxidase, increasing synaptic monoamine levels.
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
Oral: 5-10 mg once or twice daily, maximum 40 mg/day. Intramuscular: 5-10 mg every 30-60 minutes as needed, maximum 40 mg/day.
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults (range 4-8 hours). Clinically, duration of action correlates with half-life, but tolerance may develop with repeated dosing.
2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect
Renal (30-40% unchanged, pH-dependent), with minor biliary/fecal elimination. At acidic urine pH, elimination half-life is shortened; at alkaline pH, reabsorption increases.
Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible
Category C
Category C
CNS Stimulant
CNS Stimulant